Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
PLoS One ; 18(11): e0281221, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37948425

RESUMO

BACKGROUND: Carpal Tunnel Syndrome (CTS) is the most common compressive neuropathy, accounting for 90% of all neuropathies. Its prevalence ranges from 3.8%-7.8% in the population. The gold standard for its diagnosis is the neurophysiological study (85% sensitivity and 95% specificity), with the disadvantage of being invasive, complex and expensive, which means an increase in cost and time for the diagnosis of the disease. The main objective of this diagnostic test evaluation study is to investigate the value of ultrasound in the diagnosis of CTS, and among the secondary objectives, to establish the ultrasound parameters that are predictors of CTS in comparison with neurophysiological studies, attempting to standardize a protocol and reference values that determine the presence or absence of CTS. METHODS: Prospective, cross-sectional study. The reference test with which we compared the ultrasound is the neurophysiological test (NPT). Patients will come consecutively from the Neurophysiology Department of the Virgen Macarena Hospital, with clinical suspicion of CTS and fulfilling the inclusion/exclusion criteria. To calculate the sample size (EPIDAT program) we proposed a sensitivity of 78% and specificity of 87% with a confidence level of 95%, requiring 438 patients (264 NPT positive, 174 NPT negative). We followed an ultrasound study protocol that included the ultrasound variables: cross-sectional area at the entrance and exit of the tunnel, range of nerve thinning, wrist-forearm index, flexor retinaculum bulging, power Doppler uptake and the existence of adjacent wrists or masses. We propose a timeline for the study to be performed between 2020 and 2023. Finally, we propose a cost-effectiveness analysis. DISCUSSION: Ultrasound not only allows to objectify the alterations of the median nerve but also the underlying pathological mechanisms in CTS. A multitude of ultrasound parameters have been described that should be regarded in syndrome's study, among which we included the cross-sectional area, the range of nerve thinning, the wrist-forearm index, flexor retinaculum bulging, power Doppler uptake and assessment of anatomical alterations. The use of ultrasound as a diagnostic tool in CTS has many advantages for both doctors and the patients, as it is a non-invasive, convenient, and fast tool increasingly accessible to professionals. TRIAL REGISTRATION: Trials registry number: NCT05556278.


Assuntos
Síndrome do Túnel Carpal , Humanos , Síndrome do Túnel Carpal/diagnóstico por imagem , Síndrome do Túnel Carpal/patologia , Estudos Transversais , Nervo Mediano/diagnóstico por imagem , Nervo Mediano/patologia , Estudos de Condução Nervosa , Condução Nervosa , Estudos Prospectivos , Sensibilidade e Especificidade , Ultrassonografia , Estudos Clínicos como Assunto
2.
Rev. neurol. (Ed. impr.) ; 64(9): 407-412, 1 mayo, 2017. tab, ilus
Artigo em Espanhol | IBECS | ID: ibc-162607

RESUMO

Introducción. El síndrome de Guillain-Barré se define clásicamente como una polirradiculopatía aguda simétrica ascendente, si bien existen variantes atípicas que dificultan el diagnóstico. Casos clínicos. Se recogen las historias clínicas de seis pacientes de nuestra área hospitalaria durante el primer trimestre de 2013. Se han realizado punciones lumbares, electroneurograma-electromiograma y analíticas con autoinmunidad en todos los casos. El conjunto de la muestra destaca por la presencia de características atípicas, como hiporreflexia tardía, mayor frecuencia de asimetría y afectación distal, así como fiebre inicial. Desde el punto de vista neurofisiológico, todos los pacientes presentan formas axonales de tipo sensitivomotoras y las alteraciones de la onda F son el dato más precoz. Se identifica una variante de síndrome de Miller Fisher asociada a paresia faciocervicobraquial y síndrome de vasoconstricción cerebral reversible. Otro caso aúna las variantes de paresia braquial bilateral y polirradiculopatía lumbar en el contexto de infección aguda por influenza A. La variante saltatoria ha sido demostrada en otro paciente. Todos los pacientes han recibido tratamiento con inmunoglobulinas, y en dos de ellos se sumó la plasmaféresis como terapia adicional. Conclusiones. La agrupación de seis casos axonales con características clínicas atípicas justifica la necesidad del conocimiento de estas variantes para lograr un diagnóstico y un tratamiento precoz. La hiporreflexia tardía y las formas faciocervicobraquiales, saltatorias y lumbares deben considerarse dentro del espectro del síndrome de Guillain-Barré. El estudio etiológico debe incluir el cribado de numerosos patógenos, entre los que debe incluirse el virus influenza (AU)


Introduction. Guillain-Barré syndrome is classically defined as a symmetrical ascending acute polyradiculoneuropathy, although there are atypical variants that make diagnosis difficult. CASE REPORTS. The medical data of six patients in our hospital area are collected during the first quarter of 2013. Lumbar punctures, imaging, neurophysiological studies, ganglioside antibodies and serologies have been proposed in all cases. We focus on the atypical features as late hyporeflexia, increased frequency of asymmetry and distal paresis and initial fever. From a neurophysiological point of view, all patients presented sensorimotor axonal forms. The most consistent datas in early studies is the F wave’s alteration. A Miller Fisher variant associated with faciocervicobraquial paresis and cerebral reversible vasoconstriction syndrome has been detected. A bilateral brachial paresis and lumbar polyradiculopathy in the context of influenza A infection is other interesting case. The saltatory variant with cranial nerve involvement and lower limbs paresis has been demonstrated in one patient. Bands in cerebrospinal fluid are positive in three cases and anti-ganglioside antibodies in one patient. The syndrome of inappropriate secretion of antidiuretic hormone may explain some of the hyponatremias registered. The first line of treatment are inmunoglobulins in all patients. Plasmapheresis exchanges has been used as an additional therapy in four cases. Conclusions. These clusters of six axonal cases with atypical clinical features justifies the need for knowledge of these variants in order to achieve an early treatment. Late hyporeflexia and brachialfaciocervico, saltatory and lumbar forms should be considered in the spectrum of Guillain-Barré syndrome. The etiological study should rule out a lots of pathogens as influenza (AU)


Assuntos
Humanos , Síndrome de Guillain-Barré/diagnóstico , Síndrome de Miller Fisher/diagnóstico , Grupos Diagnósticos Relacionados , Polirradiculopatia/classificação , Diagnóstico Diferencial , Programas de Rastreamento/métodos , Técnicas Microbiológicas
3.
Mov Disord ; 23(8): 1130-6, 2008 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-18442107

RESUMO

Continuous subcutaneous apomorphine infusion (CSAI) is, at present, an alternative option for advanced Parkinson's disease (PD) with motor fluctuations. We studied the evolution of patients with PD and severe motor fluctuations long-term treated with CSAI. We reviewed data from 82 patients with PD (mean age, 67 +/- 11.07; disease duration, 14.39 +/- 5.7 years) and severe motor fluctuations referred to 35 tertiary hospitals in Spain. These patients were long-term treated (for at least 3 months) with CSAI and tolerated the procedure without serious side effects. We compared the baseline data of these 82 patients (before CSAI) with those obtained from the last follow-up visit of each patient. The mean follow-up of CSAI was 19.93 +/- 16.3 months. Mean daily dose of CSAI was 72.00 +/- 21.38 mg run over 14.05 +/- 1.81 hours. We found a statistically significant reduction in off-hours, according to self-scoring diaries (6.64 +/- 3.09 vs. 1.36 +/- 1.42 hours/day, P < 0.0001), total and motor UPDRS scores (P < 0.0001), dyskinesia severity (P < 0.0006), and equivalent dose of antiparkinsonian therapy (1,405 +/- 536.7 vs. 800.1 +/- 472.9 mg of levodopa equivalent units P < 0.0001). CSAI is an effective option for patients with PD and severe fluctuations, poorly controlled by conventional oral drug treatment.


Assuntos
Antiparkinsonianos/administração & dosagem , Apomorfina/administração & dosagem , Doença de Parkinson/tratamento farmacológico , Atividades Cotidianas/classificação , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Seguimentos , Marcha/efeitos dos fármacos , Humanos , Bombas de Infusão , Assistência de Longa Duração , Masculino , Pessoa de Meia-Idade , Atividade Motora/efeitos dos fármacos , Exame Neurológico/efeitos dos fármacos , Doença de Parkinson/diagnóstico , Resultado do Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...